Get to know our clinical trials
Clinical trial conducted in humans to evaluate the safety of BAY 3713372 and how it works in participants with solid tumors with MTAP gene deletion
THE AIM OF THIS TRIAL IS: -TO SEE WHETHER THE NEW TREATMENT BAY 3713372 HAS ANY EFFECT, GOOD OR BAD. -TO FIND THE BEST DOSE OF BAY 3713372 TO GIVE TO PARTICIPANTS. -TO UNDERSTAND WHAT HAPPENS TO BAY 3713372 ONCE IT IS IN THE BODY. -TO UNDERSTAND HOW THE DRUG AFFECTS YOUR BODY. -TO UNDERSTAND HOW THE TREATMENT AFFECTS YOUR DISEASE. -TO LEARN HOW DIFFERENT TYPES AND AMOUNTS OF FOOD AFFECT THE WAY THE BODY ABSORBS THE TRIAL DRUG.
Technical Summary
- FIRST-IN-HUMAN TRIAL TO EVALUATE THE SAFETY OF BAY 3713372 AND HOW IT WORKS IN PARTICIPANTS WITH SOLID TUMORS WITH MTAP GENE DELETION.
- Code EudraCT: 2025-520623-24-00
- Protocol number: 22931
- Promoter: Bayer Hispania S.L
- Molecule/Drug: BAY 3713372
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.